Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
Altamira Therapeutics (Nasdaq: CYTO), a company specializing in nanoparticle-based RNA delivery technology, has announced its upcoming First Half 2024 Financial Results and Business Update Call. The event is scheduled for Tuesday, September 24, 2024, at 8:30 am ET.
Key participants in the call will be Founder, Chairman, and CEO Thomas Meyer, along with COO Covadonga Pañeda. They will present prepared remarks followed by a Q&A session open to investors and analysts.
Interested parties can access the webcast through the provided URL. Additionally, a registration link is available for those who wish to join the call via phone. Multiple options for joining are offered, including dial-in with a unique PIN and a 'Call Me' feature. A replay of the call will be accessible through the webcast link after the live event concludes.
Altamira Therapeutics (Nasdaq: CYTO), un'azienda specializzata nella tecnologia di somministrazione di RNA basata su nanoparticelle, ha annunciato la prossima Chiamata per i Risultati Finanziari e Aggiornamenti Aziendali del Primo Semestre del 2024. L'evento è previsto per martedì 24 settembre 2024, alle 8:30 ET.
I partecipanti chiave alla chiamata saranno Fondatore, Presidente e CEO Thomas Meyer, insieme a COO Covadonga Pañeda. Presenteranno osservazioni preparate seguite da una sessione di Domande e Risposte aperta a investitori e analisti.
Le parti interessate possono accedere al webcast tramite l'URL fornito. Inoltre, è disponibile un link di registrazione per coloro che desiderano unirsi alla chiamata telefonicamente. Sono offerti molteplici opzioni per partecipare, inclusa la chiamata con un PIN unico e una funzione 'Chiamami'. Una registrazione della chiamata sarà accessibile tramite il link del webcast dopo la conclusione dell'evento dal vivo.
Altamira Therapeutics (Nasdaq: CYTO), una compañía especializada en tecnología de entrega de ARN basada en nanopartículas, ha anunciado su próxima Llame para Resultados Financieros y Actualización Empresarial del Primer Semestre de 2024. El evento está programado para martes, 24 de septiembre de 2024, a las 8:30 a.m. ET.
Los principales participantes de la llamada serán Fundador, Presidente y CEO Thomas Meyer, junto con COO Covadonga Pañeda. Presentarán comentarios preparados seguidos de una sesión de preguntas y respuestas abierta a inversores y analistas.
Las partes interesadas pueden acceder al webcast a través de la URL proporcionada. Además, hay un enlace de registro disponible para aquellos que deseen unirse a la llamada por teléfono. Se ofrecen múltiples opciones para unirse, incluida la marcación con un PIN único y una función 'Llámame'. Una grabación de la llamada estará accesible a través del enlace del webcast después de que finalice el evento en vivo.
Altamira Therapeutics (Nasdaq: CYTO)는 나노 입자를 기반으로 한 RNA 전달 기술을 전문으로 하는 회사로, 다가오는 2024년 상반기 재무 결과 및 비즈니스 업데이트 전화 회의를 발표했습니다. 이 행사는 2024년 9월 24일 화요일, 오전 8:30 ET에 예정되어 있습니다.
회의의 주요 참가자는 창립자, 회장 및 CEO Thomas Meyer와 COO Covadonga Pañeda입니다. 그들은 준비된 발언을 하고 투자자 및 분석가를 위한 질문과 답변 세션을 진행할 것입니다.
관심 있는 분들은 제공된 URL을 통해 웹캐스트에 접속할 수 있습니다. 전화로 회의에 참여하고자 하는 분들을 위한 등록 링크도 제공됩니다. 고유한 PIN으로 전화 연결 및 '저에게 전화하기' 기능을 포함하여 여러 가지 참여 방법이 제공됩니다. 실시간 이벤트가 종료된 후 웹캐스트 링크를 통해 회의의 재생이 가능합니다.
Altamira Therapeutics (Nasdaq: CYTO), une entreprise spécialisée dans la technologie de délivrance d'ARN à base de nanoparticules, a annoncé sa prochaine Conférence téléphonique sur les résultats financiers et la mise à jour des affaires du premier semestre 2024. L'événement est prévu pour mardi 24 septembre 2024, à 8h30 ET.
Les participants clés à l'appel seront Fondateur, Président et PDG Thomas Meyer, ainsi que COO Covadonga Pañeda. Ils présenteront des remarques préparées suivies d'une session de questions-réponses ouverte aux investisseurs et aux analystes.
Les parties intéressées peuvent accéder au webcast via l'URL fournie. De plus, un lien d'inscription est disponible pour ceux qui souhaitent rejoindre l'appel par téléphone. Plusieurs options pour rejoindre sont proposées, y compris la composition avec un code PIN unique et une fonction 'Appelez-moi'. Un replay de l'appel sera accessible via le lien du webcast après la fin de l'événement en direct.
Altamira Therapeutics (Nasdaq: CYTO), ein Unternehmen, das sich auf nanopartikelbasierte RNA-Übertragungstechnologien spezialisiert hat, hat seine bevorstehende Telefonkonferenz zu den Finanz Ergebnissen und Unternehmensupdates für das erste Halbjahr 2024 angekündigt. Die Veranstaltung ist für Dienstag, den 24. September 2024, um 8:30 Uhr ET angesetzt.
Die Hauptteilnehmer der Konferenz werden Gründer, Vorsitzender und CEO Thomas Meyer sowie COO Covadonga Pañeda sein. Sie werden vorbereitete Bemerkungen präsentieren, gefolgt von einer Frage- und Antwortsession, die für Investoren und Analysten offen ist.
Interessierte können auf das Webcast über die bereitgestellte URL zugreifen. Darüber hinaus gibt es einen Registrierungslink für diejenigen, die telefonisch an der Konferenz teilnehmen möchten. Mehrere Optionen zur Teilnahme werden angeboten, einschließlich der Einwahl mit einer einzigartigen PIN und einer 'Rufen Sie mich an'-Funktion. Eine Wiederholung der Konferenz wird nach dem Ende der Live-Veranstaltung über den Webcast-Link verfügbar sein.
- None.
- None.
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its First Half 2024 Financial Results and Business Update Call on Tuesday, September 24, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts.
Webcast Access:
- Event: Altamira Therapeutics First Half 2024 Financial Results and Business Update Call
- Date: Tuesday, September 24, 2024
- Time: 8:30 am ET
- Webcast URL: https://edge.media-server.com/mmc/p/4wp8659n
Registration for Call:
https://register.vevent.com/register/BI039aac00f0eb4f228e9662f9b90a1ea4
- Click on the call link and complete the online registration form.
- Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
- Select a method for joining the call:
- Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone.
- Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. The call will come from a US number.
A replay of the call will be available after the live event and accessible through the webcast link:
https://edge.media-server.com/mmc/p/4wp8659n
About Altamira Therapeutics
Altamira Therapeutics (Nasdaq: CYTO) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (OligoPhore™ / SemaPhore™ platforms). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a
Investor Contact
FAQ
When is Altamira Therapeutics (CYTO) hosting its First Half 2024 Financial Results call?
Who will be presenting during Altamira Therapeutics' (CYTO) financial results call?
How can investors access Altamira Therapeutics' (CYTO) First Half 2024 Financial Results call?
Will there be a replay available for Altamira Therapeutics' (CYTO) financial results call?
